Early studies of etoposide phosphate, a water-soluble prodrug.

abstract：:Publicly funded cancer medicines listed on the New Zealand Pharmaceutical Schedule were compared with those listed on the Australian Pharmaceutical Benefits Scheme. To quantify the health gains offered by the cancer medicines funded in Australia but not in New Zealand, clinical trial data reporting median progression-...

journal_title：Seminars in oncology

authors： Evans J,Laking G,Strother M,Wang T,Metcalfe S,Blick G,Pauls R,Crausaz S

更新日期：2016-12-01 00:00:00

abstract：:Previously untreated patients with stages I to IV, N0-3, M0 unresectable non-small cell lung cancer were randomized to arm I (conventional radiotherapy [RT], 60 Gy in 30 fractions over 6 weeks), arm II (accelerated RT, 60 Gy in 30 fractions over 3 weeks), arm III (conventional RT, as in arm I, plus carboplatin 70 mg/m...

journal_title：Seminars in oncology

authors： Bishop JF,Ball D,Crennan E,Ryan G,Davis S,Toner G,O'Brien P,Olver I

更新日期：1994-06-01 00:00:00

abstract：:Current data indicate that most elderly patients with acute myelogenous leukemia should be treated with intensive chemotherapy. Most should receive remission induction chemotherapy using cytarabine 100 to 200 mg/m2/d by constant intravenous infusion for five to seven days plus daunorubicin greater than or equal to 30 ...

journal_title：Seminars in oncology

authors： Champlin RE,Gajewski JL,Golde DW

更新日期：1989-02-01 00:00:00

abstract：:Imaging prostate cancer continues to represent a clinical challenge for both primary and recurrent disease. In the evaluation of the persistent/recurrent/metastatic prostate cancer, knowledge of cancer location (local v distant), size, and extent are essential in order to design a treatment, tailored to each patient's...

journal_title：Seminars in oncology

authors： Hricak H,Schöder H,Pucar D,Lis E,Eberhardt SC,Onyebuchi CN,Scher HI

更新日期：2003-10-01 00:00:00

abstract：:The effectiveness of current chemotherapeutic approaches for the treatment of solid tumors has reached a near plateau, suggesting we are nearing the limit of cytoreduction. It is hypothesized that this may be due to "subset effect," and that drugs administered according to responses predicted for particular subgroups ...

journal_title：Seminars in oncology

authors： Paik S

更新日期：2001-06-01 00:00:00

abstract：:Intra-arterial (IA) therapies for hepatocellular carcinoma (HCC) are considered palliative and should be offered to patients with intermediate-stage multinodular disease and with sufficient liver reserve. They include transarterial chemoembolization (TACE) or bland embolization, transarterial chemotherapy, and transar...

journal_title：Seminars in oncology

authors： Tsochatzis EA,Germani G,Burroughs AK

更新日期：2010-04-01 00:00:00

abstract：:The treatment for patients with unknown primary carcinoma, particularly those with unfavorable prognosis factors, has changed in the last decade, and continues to evolve. Empiric chemotherapy trials reported since 2000 with the newer drugs have improved the overall survival compared to retrospective historical data an...

journal_title：Seminars in oncology

authors： Greco FA,Pavlidis N

更新日期：2009-02-01 00:00:00

abstract：:Solid organ tumors associated with neoangiogenesis, as measured by increased microvessel density (MVD), have poorer prognoses. A similar observation of increased MVD has been made in hematologic malignancies; however, its prognostic significance remains unknown. We investigated changes in MVD in 122 newly diagnosed mu...

journal_title：Seminars in oncology

authors： Munshi NC,Wilson C

更新日期：2001-12-01 00:00:00

abstract：:Docetaxel (Taxotere, Rhône-Poulenc Rorer, Antony, France) is highly effective in the first-line treatment of metastatic breast cancer, achieving an objective response rate of 61% (95% confidence interval, 52% to 69%). This rate of response is seen in patients with poor prognostic factors such as liver metastases and m...

journal_title：Seminars in oncology

authors： Trudeau ME

更新日期：1999-06-01 00:00:00

abstract：:Many novel antifolate compounds with unique pharmacologic properties are currently in clinical development. These newer antifolates differ from methotrexate, the most widely used and studied drug in this class, in terms of their lipid solubility and cellular transport affinity, their level of polyglutamation, and thei...

journal_title：Seminars in oncology

authors： Takimoto CH

更新日期：1997-10-01 00:00:00

abstract：:Treatment of hormone-refractory prostate cancer (HRPC) historically has shown limited efficacy. However, taxane-based chemotherapy regimens recently have demonstrated more promising results. Several groups have reported significant efficacy and minimal toxicity in patients with hormone-refractory disease receiving est...

journal_title：Seminars in oncology

authors： Oh WK,Kantoff PW

更新日期：1999-10-01 00:00:00

abstract：:Oligodendroglial tumors are relatively rare, comprising approximately 5% of all glial neoplasms. Oligodendroglial tumor patients have a better prognosis than those with astrocytic neoplasms, and patients with tumors that contain 1p/19q co-deletions or IDH-1 mutations appear to be particularly sensitive to treatment. I...

journal_title：Seminars in oncology

authors： Jaeckle KA

更新日期：2014-08-01 00:00:00

abstract：:Thus, many interesting and promising techniques are now available for the study of potential prognostic factors in esophageal carcinoma, and the results may supplement the information that is obtained by routine histopathologic analysis. It may become possible to define subgroups of patients with lower risk tumors, fo...

journal_title：Seminars in oncology

authors： Klimstra DS

更新日期：1994-08-01 00:00:00

abstract：:Myeloid neoplasms are characterized by acquired somatic mutations and epigenetic alterations in genes that are crucial for hematopoietic differentiation and cellular proliferation and survival pathways. The heterogeneity and genetic complexity of these disorders is daunting, but the improvement in our knowledge of the...

journal_title：Seminars in oncology

authors： Odenike O,Thirman MJ,Artz AS,Godley LA,Larson RA,Stock W

更新日期：2011-04-01 00:00:00

abstract：:In patients with recurrent, previously irradiated head and neck cancer, the traditional therapy of palliative single- or multi-agent chemotherapy yields a 30% to 40% response rate with median survival durations of 8 to 10 months. However, long-term survival is rarely observed. Reirradiation with or without concurrent ...

journal_title：Seminars in oncology

authors： Chmura SJ,Milano MT,Haraf DJ

更新日期：2004-12-01 00:00:00

abstract：:Skin findings can serve as a clue to internal disease. In this article, cutaneous manifestations of underlying lung malignancy are reviewed. Paraneoplastic dermatoses are rare, but when recognized early, can lead to early diagnosis of an underlying neoplasm. Malignancy-associated dermatoses comprise a broad group of h...

journal_title：Seminars in oncology

authors： Owen CE

更新日期：2016-06-01 00:00:00

abstract：:Hypercalcemia, a complication that develops in 10% to 20% of patients with cancer, results from disruption of the normal physiologic mechanisms that closely regulate calcium homeostasis. Most patients with hypercalcemia are seriously dehydrated, and this volume depletion further compromises the kidney's ability to exc...

journal_title：Seminars in oncology

authors： Ritch PS

更新日期：1990-04-01 00:00:00

abstract：:In order to correlate changes in morphology to changes in molecular attributes, we constructed a tissue microarray of thin and thick melanomas selected to represent progression from dysplasia to early and advanced melanoma. Hematoxylin and eosin (H&E) staining and immunohistology with antibodies to cyclin D1, p16, Ki6...

journal_title：Seminars in oncology

authors： Tuthill RJ,Reed RJ

更新日期：2007-12-01 00:00:00

abstract：:Recently, a randomized study conducted by the Gynecologic Oncology Group (GOG 111) demonstrated that, given by a 24-hour infusion, the combination of cisplatin and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is superior to combination cisplatin/cyclophosphamide in previously untreated patients with...

journal_title：Seminars in oncology

authors： Meerpohl HG,du Bois A,Luck HJ,Kühnle H,Möbus V,Kreienberg R,Bauknecht T,Köchli O,Bochtler H,Diergarten K

更新日期：1997-02-01 00:00:00

abstract：:Activation of mammalian target of rapamycin (mTOR) signaling occurs in a wide variety of human tumors and can lead to increased susceptibility to mTOR inhibitors. Temsirolimus, a novel analog of rapamycin, has shown promising preclinical and early clinical anti-tumor activity in various solid and hematologic tumor typ...

journal_title：Seminars in oncology

authors： Dancey JE,Curiel R,Purvis J

更新日期：2009-12-01 00:00:00

abstract：:This presentation represents consensus recommendations for the treatment of patients with Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the second International Workshop held in Athens, Greece during September 2002. The faculty adopted the following statements for the management of pati...

journal_title：Seminars in oncology

authors： Gertz MA,Anagnostopoulos A,Anderson K,Branagan AR,Coleman M,Frankel SR,Giralt S,Levine T,Munshi N,Pestronk A,Rajkumar V,Treon SP

更新日期：2003-04-01 00:00:00

abstract：:Single-agent gemcitabine remains the standard treatment for advanced pancreatic cancer. Recent phase III trials have failed to show improvements in survival using gemcitabine in combination with other chemotherapeutic agents, although the gemcitabine/oxaliplatin combination has shown some promise. The combination of g...

journal_title：Seminars in oncology

authors： Burris HA 3rd

更新日期：2005-08-01 00:00:00

abstract：:The purpose of this pilot study was to determine the safety and feasibility of accelerated fractionation (via concomitant boost) radiotherapy (XRT) with concurrent carboplatin/paclitaxel chemotherapy for locally advanced stage III non-small cell lung carcinoma. Radiotherapy consisted of 3-dimensional conformal techniq...

journal_title：Seminars in oncology

authors： Machtay M,Washam C,Devine P

更新日期：2005-04-01 00:00:00

abstract：:Immune dysregulation, a hallmark of chronic lymphocytic leukemia (CLL), manifests itself in three autoimmune diseases: warm autoimmune hemolytic anemia (AIHA); idiopathic thrombocytopenia (ITP); and, pure red cell aplasia (PRCA). AIHA occurs in 11% of advanced stage CLL patients. Prednisone is the first treatment of c...

journal_title：Seminars in oncology

authors： Diehl LF,Ketchum LH

更新日期：1998-02-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 1-hour infusion potentially offers its recipients reduced toxicity, demonstrated efficacy, and greater ease of administration. To confirm this hypothesis, we undertook a phase I/II study of 1-hour, single-agent paclitaxel in 164 patients' refra...

journal_title：Seminars in oncology

authors： Hainsworth JD,Greco FA

更新日期：1995-12-01 00:00:00

abstract：:We report an update on a prospective observational trial for Waldenstrom's macroglobulinemia (WM) that called for re-registration to treatment with fludarabine (30 mg/m(2)) upon the development of symptomatic or progressive disease. Patients who did not require therapy for more than 1 year (n = 54) could be distinguis...

journal_title：Seminars in oncology

authors： Dhodapkar MV,Jacobson JL,Gertz MA,Crowley JJ,Barlogie B

更新日期：2003-04-01 00:00:00

abstract：:Phase I studies of CPT-11 (irinotecan) have been conducted in Europe, the United States, and Japan to determine the maximum tolerated dose (MTD) and the most appropriate intravenous administration schedule for further evaluation in phase II investigations. Diarrhea and/or neutropenia were the major dose-limiting toxic...

journal_title：Seminars in oncology

authors： Armand JP

更新日期：1996-02-01 00:00:00

abstract：:The use of adjuvant radiation therapy and chemotherapy diminishes the likelihood of local-regional and distant recurrences and appears to prolong survival in patients who have undergone a complete surgical resection of a Dukes-Kirklin stage B2 or C rectal cancer. Patients with this malignant condition rarely develop p...

journal_title：Seminars in oncology

authors： Mayer RJ

更新日期：1985-09-01 00:00:00

abstract：:The outcome of chemotherapy for patients with stage IV melanoma is unsatisfactory, since durable responses are rarely achieved. More experimental treatments, such as vaccine approaches, antibody treatments, and gene therapy are being developed and are of high scientific interest; however, their efficacy in advanced me...

journal_title：Seminars in oncology

authors： Keilholz U,Gore ME

更新日期：2002-10-01 00:00:00

abstract：:The combination of gemcitabine and docetaxel exhibits good activity in the treatment of advanced breast cancer. Phase II trial response rates using 21- or 28-day schedules have ranged from 36% to 79% in patient populations with varying degrees of pretreatment. In studies of extensively pretreated anthracycline-resista...

journal_title：Seminars in oncology

authors： Fumoleau P

更新日期：2003-04-01 00:00:00